What is HC Wainwright's Forecast for ODTX FY2026 Earnings?

Key Points

• HC Wainwright forecasts Odyssey Therapeutics will lose $6.20 per share in FY2026, close to the current consensus estimate of a $6.18 loss. It also projects losses of $5.14 per share in FY2027 and $4.83 in FY2030.
• HC Wainwright maintains a Buy rating and $40 price target. Across analysts, ODTX has a “Moderate Buy” consensus rating and an average target of $34.67.
• ODTX shares opened at $19.15, with a 52-week range of $15.10–$29.05 and a market capitalization of about $920 million.

Odyssey Therapeutics, Inc. (NASDAQ:ODTX - Free Report) - Equities researchers at HC Wainwright issued their FY2026 earnings estimates for shares of Odyssey Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of ($6.20) per share for the year. HC Wainwright currently has a "Buy" rating and a $40.00 price objective on the stock. The consensus estimate for Odyssey Therapeutics' current full-year earnings is ($6.18) per share. HC Wainwright also issued estimates for Odyssey Therapeutics' Q4 2026 earnings at ($1.26) EPS, FY2027 earnings at ($5.14) EPS, FY2028 earnings at ($5.03) EPS, FY2029 earnings at ($5.22) EPS and FY2030 earnings at ($4.83) EPS.

ODTX has been the subject of several other research reports. Weiss Ratings assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They set a "sell (d+)" rating on the stock. Raymond James Financial initiated coverage on shares of Odyssey Therapeutics in a research report on Thursday, October 8th. They set an "outperform" rating and a $42.00 target price on the stock. UBS Group initiated coverage on shares of Odyssey Therapeutics in a report on Monday, October 12th. They issued a "buy" rating and a $27.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of Odyssey Therapeutics from $26.00 to $29.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Odyssey Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $34.67.

Odyssey Therapeutics Price Performance

Shares of ODTX opened at $19.15 on Tuesday. The company has a 50-day moving average of $21.08. The stock has a market cap of $920.35 million and a P/E ratio of -2.83. Odyssey Therapeutics has a 52-week low of $15.10 and a 52-week high of $29.05.

Hedge Funds Weigh In On Odyssey Therapeutics

A number of institutional investors have recently made changes to their positions in ODTX. Russell Investments Group Ltd. acquired a new stake in shares of Odyssey Therapeutics during the third quarter valued at $28,000. Aberdeen Group plc increased its position in Odyssey Therapeutics by 4.7% during the 3rd quarter. Aberdeen Group plc now owns 172,771 shares of the company's stock worth $3,839,000 after purchasing an additional 7,771 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Odyssey Therapeutics during the 2nd quarter worth about $601,000. State Street Corp acquired a new position in Odyssey Therapeutics in the 2nd quarter valued at about $1,477,000. Finally, Citadel Advisors LLC acquired a new position in Odyssey Therapeutics in the 2nd quarter valued at about $4,162,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a biotechnology company focused on discovering and developing medicines for inflammatory and autoimmune diseases. Its research centers on the immune system and biological pathways that may be targeted to address these conditions.

Founded in 2021, the company uses drug-discovery capabilities to identify and advance potential therapies. Its business is research and development rather than the sale of marketed medicines.

Odyssey is based in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.